The A2 Milk Company Ltd (ASX: A2M) share price is down 9% after the business gave a trading update at its AGM.
A2 Milk is a New Zealand-based dairy business with a focus on infant formula and liquid milk.
Trading update
The company noted that it had already announced earlier this year that the company was impacted by shortfalls of Chinese-labelled infant formula products that materially impacted product availability during the FY26 fourth quarter.
This led to a large proportion of existing users to switch to alternative brands, which is impacting FY27 infant formula sales.
On top of that, English label infant formula offtake was indirectly impacted by the USA label infant formula recall announced in May 2026.
A2 Milk said it has been focused on recovering in China. Its Chinese-label offtake has recovered to around 50% of pre-supply chain disruptions, up from 40% in August 2026.
Outlook for the A2 Milk share price
The company said that it still expects revenue and EBITDA (EBITDA explained) to grow in FY27, supported by “increased contribution from product innovation” and new markets, continued momentum in ‘other nutritionals’ and ‘liquid milk’ and profitability improvements at a2 Pokeno.
At this stage, the company expects FY27 infant formula sales to be broadly similar to FY26, supported by the launch of two new Chinese products, an updated a2 Platinum product and the pending resolution of the China importation requirements currently impacting a2 Genesis.
A2 Milk said the infant formula recovery will be supported by an increase in marketing, particularly in the first half of FY27. With that in mind, revenue and EBITDA is expected to be “materially weighted” to the second half of FY27.
The transition for the a2 Platinum product is tracking to its plan, with one-off transformation costs now expected to be around $15 million in FY27.
While a range of outcomes is now possible, the company gave some guidance for FY27.
Revenue growth is expected in the mid-single digits, with HY27 revenue expected to be slightly down.
The underlying EBITDA margin is expected to be approximately 15%, with HY27 “materially down” compared to HY26.
The A2 Milk share price has lost some of the gains of the last six months. It’s hard to say if it’s good value or not because the infant formula industry doesn’t seem to be consistent in China, plus births seem to be reducing over time.
It’s not one of the ASX growth shares on my own buy list, but if it can regain its lost market share in China, it could be an underrated buy today.





